Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Gokhan, Erdem"'
Autor:
Gokhan Erdem, Nuri Karadurmus, Sukru Ozaydin, Ibrahim Demirci, Bilgin Bahadir Basgoz, İsmail Ertürk, Birol Yıldız, Ramzan Ocal, Fikret Arpaci
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 1, Pp 29-34 (2018)
Background: Lung involvement, an uncommon initial presentation of Hodgkin Lymphoma (HL), may appear as primary or secondary pulmonary HL. Although the combination of Brentuximab vedotin (BV) with AVD is suggested as an alternative treatment to combin
Externí odkaz:
https://doaj.org/article/1d537572ca9c4655b232a11086d56df5
Autor:
Yasar Subutay Peker, Mehmet Fatih Can, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, Sedat Gurkok, Alper Gozubuyuk, Onur Genc, Gokhan Erdem, Ahmet Ozet, Mustafa Gerek, Yusuf Peker
Publikováno v:
Case Reports in Surgery, Vol 2018 (2018)
The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In
Externí odkaz:
https://doaj.org/article/17753d1cf366468c9b94b7a4d65b2878
Autor:
Musa Baris Aykan, Halil Kizilöz, Galip Buyukturan, Gokhan Erdem, Ramazan Esen, Ramazan Acar, Yuksel Urun, Fikret Arpaci, Ismail Erturk, Birol Yildiz, Nuri Karadurmus
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(7)
Introduction and aim To demonstrate the real-life data about patients who underwent AHSCT due to GCT. Methods Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research
Autor:
Bilgin Bahadir Basgoz, Ramzan Ocal, Sukru Ozaydin, Ibrahim Demirci, Fikret Arpaci, Gokhan Erdem, Ismail Erturk, Nuri Karadurmus, Birol Yildiz
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 1, Pp 29-34 (2018)
Background: Lung involvement, an uncommon initial presentation of Hodgkin Lymphoma (HL), may appear as primary or secondary pulmonary HL. Although the combination of Brentuximab vedotin (BV) with AVD is suggested as an alternative treatment to combin
Autor:
Kutan Kavakli, Mehmet Fatih Can, Sedat Gürkök, Yusuf Peker, Mustafa Gerek, Nazif Zeybek, Onur Genç, Yaşar Subutay Peker, İsmail Hakkı Özerhan, Gokhan Yagci, Alper Gözübüyük, Ahmet Ozet, Gokhan Erdem
Publikováno v:
Case Reports in Surgery
Case Reports in Surgery, Vol 2018 (2018)
Case Reports in Surgery, Vol 2018 (2018)
The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In
Autor:
Ilker Tasci, Teoman Dogru, Alper Sonmez, Halil Genc, Selim Kilic, Abdullah Olgun, Mahmut Gok, Gokhan Erdem, Selahattin Erikci
Publikováno v:
Mediators of Inflammation, Vol 2006 (2006)
Unlike diabetes mellitus and impaired glucose tolerance, it is not clear whether the subjects with impaired fasting glucose (IFG) are at increased risk of atherosclerosis and cardiovascular diseases. The CD40-CD40 ligand interaction is involved in th
Externí odkaz:
https://doaj.org/article/67f98a7fd494493b9c009e35c7e92895
Autor:
Mustafa Öztürk, Gokhan Erdem, Gürkan Mert, Ramazan Gümral, Fikret Arpaci, Nuri Karadurmus, Ismail Erturk, Sukru Ozaydin, Birol Yildiz, Selmin Ataergin
Publikováno v:
British Journal of Medicine and Medical Research. 19:1-5
Autor:
Sukru Ozaydin, Ismail Erturk, Yuksel Urun, Ramazan Esen, Gokhan Erdem, Nuri Karadurmus, B. Bahadır Başgöz, Birol Yildiz, Zeki Gokhan Surmeli, Oğuz Hançerlioğulları, Betül Tosun
Aims: Germ cell tumors (GCT) are the most common malignancies, especially in males of 15 to 35 years of age. Tandem autologous hematopoietic stem cell transplantation (AHSCT) with carboplatin and etoposide (CE) has been performed for many years in re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50e97f3875f94300291f7b3b02210a0c
https://hdl.handle.net/20.500.11782/1420
https://hdl.handle.net/20.500.11782/1420
Autor:
Ramazan Acar, Ismail Erturk, Birol Yildiz, Murat Urkan, Nuri Karadurmus, Ramazan Esen, Betül Tosun, Gokhan Erdem
Aims: Testicular tumors are one of the most common malignancies in males, between 15 and 35 years of age. Testicular cancer patients are treated with the combination of gemcitabine, oxaliplatin and paclitaxel (GOP) in relapsed and refractory disease,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bfa312ba4e00726939e5ecd91dd207a
https://hdl.handle.net/20.500.11782/1163
https://hdl.handle.net/20.500.11782/1163